Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries

AbstractThe ‘BOADICEA’ Web Application (BWA) used to assess breast cancer risk, is currently being further developed, to integrate additional genetic and non-genetic factors. We surveyed clinicians’ perceived acceptability of the existing BWA v3. An online survey was conducted through the BOADICEA website , and the British, Dutch, French and Swedish genetics societies. Cross-sectional data from 443 participants who provided at least 50% responses were analysed. Respondents varied in age and, clinical seniority, but mainly comprised women (77%) and genetics professionals (82%). Some expressed negativ e opinions about the scientific validity of BOADICEA (9%) and BWA v3 risk presentations (7–9%). Data entry time (62%), clinical utility (22%) and ease of communicating BWA v3 risks (13–17%) received additional negative appraisals. In multivariate analyses, controlling for gender and country, dat a entry time was perceived as longer by genetic counsellors than clinical geneticists (p <  0.05). Respondents who (1) considered hormonal BC risk factors as more important (p <  0.01), and (2) communicated numerical risk estimates more frequently (p <  0.001), judged BWA v3 of lower clinical utility. Respondents who carried out less frequent clinical activity (p <  0.01) and respondents with ‘11 to 15 years’ seniority (p <  0.01) had less favourable opinions of BWA v3 risk presentations. Seniority of ‘6 to 10 years’ (p <  0.05) ...
Source: Familial Cancer - Category: Cancer & Oncology Source Type: research